Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8796427 Humanized anti-human NKG2A monoclonal antibody

Patent 8796427 was granted and assigned to Novo Nordisk on August, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Novo Nordisk

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

87964270

Patent Inventor Names

Jianhe Chen0

Jinchao Zhang0

Jing Su0

Jiujiu Yu0

Petrus Johannes Louis Spee0

Søren Berg Padkjær0

Date of Patent

August 5, 2014

Patent Application Number

128119900

Date Filed

January 23, 2009

Patent Citations Received

‌

US Patent 11679132 Methods for enhancing efficacy of therapeutic immune cells

‌

US Patent 12129485 Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies

‌

US Patent 12077584 Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)

‌

US Patent 11981734 Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)

Patent Primary Examiner

‌

Zachary Skelding

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8796427 Humanized anti-human NKG2A monoclonal antibody

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API